About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 6645 record(s)
Req # A-2020-000851
Adverse Reaction Reports (AERs). Report numbers: E2B_03199841, E2B_03206799, E2B_03207460, E2B_03222251.Organization: Health Canada
January 2021
Req # A-2020-000856
Adverse Reaction Reports (AERs). Report numbers: E2B_03207491; E2B_03209790; E2B_03212224; E2B_03212536.Organization: Health Canada
January 2021
Req # A-2020-000857
Adverse Reaction Reports (AERs). Report numbers: E2B_02836616, E2B_02864251, E2B_02854101, 000911607, E2B_03042781, E2B_03045681, E2B_03051219, 000908424, E2B_03063606, E2B_03125521.Organization: Health Canada
January 2021
Req # A-2020-000868
Adverse Reaction Report (AER) for C1 Esterase Inhibitor (Human). Report number: E2B_03184173. ADRs for GAMMAGARD LIQUID: 000914469, E2B_03202144. ADRs for Mesalazine: E2B_03203957, E2B_03208437. ADRs for VYVANSE: E2B_03174445, E2B_03175996,…Organization: Health Canada
January 2021
Req # A-2020-000877
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-106968-891.Organization: Health Canada
January 2021
Req # A-2020-000895
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-108363-178, Shared Services Partnership.Organization: Health Canada
January 2021
Req # A-2020-000984
Adverse Reaction Reports (AERs) for Diclectin (doxylamine succinate / pyridoxine hydrochloride). Report numbers: E2B_01670148, 000717866, 000725413, 000725643, 000731573, 000910928, 731742, 732045.Organization: Health Canada
January 2021
Req # A-2020-001003
Adverse Reaction Reports (AERs). Report numbers: E2B_03233685, E2B_03052450, E2B_03140323, E2B_03258952, 000909974, E2B_03159242, E2B_02924578, E2B_03166422, E2B_03166758, E2B_03075414.Organization: Health Canada
January 2021
Req # A-2020-001004
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-107838-561, Classification Action Infectious Disease Prevention and Control Branch.Organization: Health Canada
January 2021
Req # A-2020-001077
Adverse Reaction Report (AER) for PETHIDINE HYDROCHLORIDE. Report number: E2B_02184075.Organization: Health Canada
January 2021